

**PB 102 of 2024**

National Health (Minimum Stockholding) Amendment Determination (No. 9) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 26 September 2024

Nikolai Tsyganov

Assistant Secretary  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division  
Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments commencing 1 October 2024 2

National Health (Minimum Stockholding) Determination 2023 2

Schedule 2—Amendments commencing immediately after the commencement of Schedule 2 to the *National Health (Minimum Stockholding) Amendment Determination (No. 4) 2024* – 1 October 2024 15

National Health (Minimum Stockholding) Determination 2023 15

Schedule 3—Amendments commencing immediately after the commencement of Schedule 3 to the *National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024* – 1 December 2024 16

National Health (Minimum Stockholding) Determination 2023 16

1 Name

(1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 9) 2024*.

(2) This instrument may also be cited as PB 102 of 2024.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 October 2024. | 1 October 2024 |
| 2. Schedule 1 | 1 October 2024. | 1 October 2024 |
| 3. Schedule 2 | Immediately after the commencement of Schedule 2 to the *National Health (Minimum Stockholding) Amendment Determination (No. 4) 2024*. | 1 October 2024 |
| 4. Schedule 3 | Immediately after the commencement of Schedule 3 to the *National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024*. | 1 December 2024 |

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 October 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Abacavir with lamivudine | Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg | Oral | ABACAVIR/LAMIVUDINE 600/300 SUN | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

2 Schedule 1 (table)

Before:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Acamprosate | Tablet (enteric coated) containing acamprosate calcium 333 mg | Oral | Acamprosate Viatris | after 30 July 2024—4 months stock by reference to usual demand of both Acamprosate Viatris and Acamprosate Mylan added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Abacavir with lamivudine | Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg | Oral | Abacavir/Lamivudine Viatris | after 31 December 2024—4 months stock by reference to usual demand of both Abacavir/Lamivudine Viatris and Abacavir/Lamivudine Mylan added together |

3 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Acarbose | Tablet 50 mg | Oral | GLYBOSAY | 2 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | Oral | Fosamax Plus 70 mg/140 mcg | between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | Oral | Fosamax Plus | between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand |

4 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amoxicillin | Capsule 500 mg (as trihydrate) | Oral | NOUMED AMOXICILLIN | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

5 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AlphaClav Duo Forte Viatris | after 31 August 2024—6 months stock by reference to usual demand of both Alphaclav Duo Forte Viatris and AlphaClav Duo Forte added together |

6 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amoxicillin | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral | Amoxil | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AlphaClav Duo Forte Viatris | 6 months stock by reference to usual demand |

7 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aripiprazole | Tablet 10 mg | Oral | Tevaripiprazole | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

8 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aripiprazole | Tablet 15 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aripiprazole | Tablet 15 mg | Oral | Aripic Aripiprazole | between 1 October 2024 and 31 March 2025—0 months stock by reference to usual demand |

9 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aripiprazole | Tablet 15 mg | Oral | Tevaripiprazole | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

10 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aripiprazole | Tablet 20 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aripiprazole | Tablet 20 mg | Oral | Aripic Aripiprazole | between 1 October 2024 and 31 March 2025—0 months stock by reference to usual demand |

11 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aripiprazole | Tablet 20 mg | Oral | Tevaripiprazole | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

12 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aripiprazole | Tablet 30 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aripiprazole | Tablet 30 mg | Oral | Aripic Aripiprazole | between 1 October 2024 and 31 March 2025—0 months stock by reference to usual demand |

13 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aripiprazole | Tablet 30 mg | Oral | Tevaripiprazole | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

14 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atorvastatin | Tablet 80 mg (as calcium) | Oral | Atorvastatin GH | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

15 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Benzathine benzylpenicillin | Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre-filled syringe | Injection | Bicillin L-A | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bisacodyl | Tablet 5 mg | Oral | Lax-Tab | between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand |

16 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Carmellose | Eye drops containing carmellose sodium 10 mg per mL, 15 mL | Application to the Eye | Refresh Liquigel | 4 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Carmellose | Eye drops containing carmellose sodium 10 mg per mL, 15 mL | Application to the Eye | Refresh Liquigel | between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand |

17 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 15 mL | Application to the Eye | Refresh Tears Plus | 4 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 15 mL | Application to the Eye | Refresh Tears Plus | between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand |

18 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Carmellose with glycerin | Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL | Application to the Eye | Optive | 4 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Carmellose with glycerin | Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL | Application to the Eye | Optive | between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand |

19 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cefazolin | Powder for injection 2 g (as sodium) | Injection | Cephazolin Viatris | after 30 July 2024—6 months stock by reference to usual demand of both Cephazolin Viatris and Cephazolin Alphapharm added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cefepime | Powder for injection 1 g (as hydrochloride) | Injection | Cefepime Kabi | between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand |
| Cefepime | Powder for injection 2 g (as hydrochloride) | Injection | Cefepime Kabi | between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand |

20 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ciclosporin | Oral liquid 100 mg per mL, 50 mL | Oral | Neoral | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ciprofloxacin | Tablet 250 mg (as hydrochloride) | Oral | APX-Ciprofloxacin | between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Ciprofloxacin | Tablet 500 mg (as hydrochloride) | Oral | APX-Ciprofloxacin | between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Ciprofloxacin | Tablet 750 mg (as hydrochloride) | Oral | APX-Ciprofloxacin | between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand |

21 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ciprofloxacin | Tablet 500 mg (as hydrochloride) | Oral | Cifran | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

22 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cyproterone | Tablet containing cyproterone acetate 100 mg | Oral | Pharmacor Cyproterone 100 | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
| Cyproterone | Tablet containing cyproterone acetate 50 mg | Oral | Pharmacor Cyproterone 50 | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

23 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Donepezil | Tablet containing donepezil hydrochloride 10 mg | Oral | NOUMED DONEPEZIL | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
| Donepezil | Tablet containing donepezil hydrochloride 5 mg | Oral | NOUMED DONEPEZIL | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

24 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Enalapril | Tablet containing enalapril maleate 20 mg | Oral | Enalapril generichealth | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

25 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Entecavir | Tablet 1 mg (as monohydrate) | Oral | ENTECLUDE | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Epoprostenol | Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL | Injection | Flolan | between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand |
| Epoprostenol | Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL | Injection | Flolan | between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand |

26 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Escitalopram | Tablet 20 mg (as oxalate) | Oral | APX‑Escitalopram | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | after 31 December 2024—4 months stock by reference to usual demand of both Esomeprazole Viatris and Esomeprazole Mylan added together |
| Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | after 31 December 2024—4 months stock by reference to usual demand of both Esomeprazole Viatris and Esomeprazole Mylan added together |

27 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | NOUMED ESOMEPRAZOLE | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
| Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | NOUMED ESOMEPRAZOLE | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

28 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fenofibrate | Tablet 145 mg | Oral | Fenofibrate Viatris | 6 months stock by reference to usual demand of both Fenofibrate Viatris and Fenofibrate Mylan added together |

29 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluorometholone | Eye drops 1 mg per mL, 5 mL | Application to the Eye | FML Liquifilm | between 1 July 2024 and 31 January 2025—0 months stock by reference to usual demand |

30 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gabapentin | Capsule 300 mg | Oral | Gabapentin generichealth | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
| Gabapentin | Capsule 400 mg | Oral | Gabapentin generichealth | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

31 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hydrocortisone | Tablet 20 mg | Oral | Hydrocortisone Viatris 20 | 4 months stock by reference to usual demand of both Hydrocortisone Viatris 20 and Hydrocortisone Mylan 20 added together |

32 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the Eye | In a Wink Moisturising | between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hypromellose with carbomer 980 | Ocular lubricating gel 3 mg-2 mg per g, 10 g | Application to the Eye | Genteal gel | between 1 October 2024 and 30 June 2025—0 months stock by reference to usual demand |
| Hypromellose with carbomer 980 | Ocular lubricating gel 3 mg-2 mg per g, 10 g | Application to the Eye | HPMC PAA | between 1 October 2024 and 30 June 2025—0 months stock by reference to usual demand |

33 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Insect allergen extract‑yellow jacket venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Yellow Jacket Venom | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Irbesartan | Tablet 75 mg | Oral | Karvea | between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand |

34 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Itraconazole | Capsule 100 mg | Oral | APO-Itraconazole | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Labetalol | Tablet containing labetalol hydrochloride 100 mg | Oral | Presolol 100 | between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand |

35 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lisinopril | Tablet 20 mg | Oral | Lisinopril generichealth | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

36 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lithium | Tablet containing lithium carbonate 450 mg (slow release) | Oral | Quilonum SR | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Macrogol 3350 | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | Oral | Movicol | between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand |

37 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Meloxicam | Tablet 15 mg | Oral | Pharmacor Meloxicam 15 | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

38 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Meloxicam | Tablet 7.5 mg | Oral | Pharmacor Meloxicam 7.5 | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

39 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Methylprednisolone | Injection containing methylprednisolone acetate 40 mg in 1 mL | Injection | Depo-Nisolone | between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand |

40 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nevirapine | Tablet 200 mg | Oral | Nevirapine Viatris | after 30 November 2024— 4 months stock by reference to usual demand of both Nevirapine Viatris and Nevirapine Alphapharm added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nevirapine | Tablet 400 mg (extended release) | Oral | Viramune XR | between 1 October 2024 and 30 September 2025—0 months stock by reference to usual demand |

41 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Norfloxacin | Tablet 400 mg | Oral | APO‑Norfloxacin | 2.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nortriptyline | Tablet 10 mg (as hydrochloride) | Oral | NortriTABS 10 mg | between 1 October 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Nortriptyline | Tablet 25 mg (as hydrochloride) | Oral | NortriTABS 25 mg | between 1 October 2024 and 31 December 2024—0 months stock by reference to usual demand |

42 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Acpio 45 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pregabalin | Capsule 150 mg | Oral | Cipla Pregabalin | between 1 October 2024 and 28 February 2025—0 months stock by reference to usual demand |

43 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Riluzole | Oral suspension 50 mg per 10 mL, 300 mL | Oral | Teglutik | between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand |

44 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Rizatriptan | Tablet (orally disintegrating) 10 mg (as benzoate) | Oral | APO-Rizatriptan | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
| Rizatriptan | Tablet (orally disintegrating) 10 mg (as benzoate) | Oral | Rizatriptan ODT GH | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

45 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Viread | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

46 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg | Oral | Tenofovir EMT GH | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

47 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valacor 500 | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

48 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Zoledronic Acid SUN | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |

Schedule 2—Amendments commencing immediately after the commencement of Schedule 2 to the *National Health (Minimum Stockholding) Amendment Determination (No. 4) 2024* – 1 October 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amino acid formula with vitamins and minerals without lysine and low in tryptophan | Sachets containing oral powder 24 g, 30 (GA gel) | Oral | GA gel | 6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amino acid formula with vitamins and minerals without lysine and low in tryptophan | Sachets containing oral powder 24 g, 30 (GA gel) | Oral | GA gel | 0 months stock by reference to usual PBS demand |

2 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Irbesartan with hydrochlorothiazide | Tablet 150 mg-12.5 mg | Oral | AVSARTAN HCT 150/12.5 | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Isoleucine with carbohydrate | Sachets of oral powder 4 g containing 1 g isoleucine, 30 (Isoleucine 1000) | Oral | Isoleucine 1000 | 0 months stock by reference to usual PBS demand |
| Isoleucine with carbohydrate | Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50) | Oral | Isoleucine 50 | 0 months stock by reference to usual PBS demand |

Schedule 3—Amendments commencing immediately after the commencement of Schedule 3 to the *National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024* – 1 December 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valine with carbohydrate | Sachets of oral powder 4 g containing 1 g valine, 30 (Valine 1000) | Oral | Valine 1000 | 6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valine with carbohydrate | Sachets of oral powder 4 g containing 1 g valine, 30 (Valine 1000) | Oral | Valine 1000 | 0 months stock by reference to usual PBS demand |

2 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valine with carbohydrate | Sachets of oral powder 4 g containing 50 mg valine, 30 (Valine 50) | Oral | Valine 50 | 6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valine with carbohydrate | Sachets of oral powder 4 g containing 50 mg valine, 30 (Valine 50) | Oral | Valine 50 | 0 months stock by reference to usual PBS demand |